ClinicalTrials.gg
RecruitingNCT06970912DNADalHRUpdated Jul 13, 2026

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

A Phase 2 interventional study of Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy and Taxane-Based Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer and Early-Stage Breast Cancer, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by Peking University People's Hospital — 17 open to participants now, 18 under way, none of them phase 3. Breast Neoplasms · Peking University People's Hospital.

Planned enrollment
4th of 17
393 · median 200
Started
2025
with 1 other
Phase 2
5 of 32
5 open now
Primary completion
2029-12
later than 15 of 17 live
Registered
23rd of 32
by date

Among the 32 studies in Breast Neoplasms by Peking University People's Hospital, this one is the 4th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 15 of the 17 other live ones, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 32 studies in Breast Neoplasms by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Peking University People's Hospital, or all of them as a file.
02

Study summary

  • This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer. The study aims to determine if combining the CDK4/6 inhibitor Dalpiciclib with endocrine therapy can reduce the need for chemotherapy while maintaining clinical benefits.
  • Key Details :

    1. Participants: 393 women (aged 18-75) with early-stage HR+/HER2- breast cancer at high risk of recurrence (e.g., tumor size ≥2 cm, lymph node involvement, or high-grade tumors).
    2. Design: Patients are randomized 1:4 to two groups:

      Group A (Chemotherapy) : Receives 4 cycles of taxane-based chemotherapy before surgery.

      Group B (Experimental) : Receives Dalpiciclib + aromatase inhibitor (AI) for 4 cycles pre-surgery.

      Post-surgery, treatment is adjusted based on ctDNA results.

    3. Primary Goals : Assess ctDNA clearance rate (conversion from detectable to undetectable ctDNA) after neoadjuvant therapy in Group B.

      Evaluate 3-year event-free survival (EFS) in Group B (e.g., freedom from cancer recurrence, progression, or death).

      Secondary Goals : Safety of Dalpiciclib + endocrine therapy. Tumor response rates (e.g., complete cell cycle arrest, pathological remission).

      Correlation between ctDNA clearance and long-term outcomes.

  • Why This Matters : Current guidelines recommend chemotherapy for high-risk HR+ breast cancer, but it often causes significant side effects. This study explores a personalized approach using ctDNA-a blood-based biomarker-to identify patients who may safely avoid chemotherapy without compromising survival. If successful, it could shift clinical practice toward less toxic, targeted therapies for eligible patients.
Read the detailed description

- 1. Scientific Background and Rationale: Breast cancer remains a leading cause of cancer-related morbidity and mortality globally, with hormone receptor-positive (HR+), HER2-negative (HER2-) subtypes accounting for approximately 70% of cases. While adjuvant chemotherapy is standard for high-risk early-stage HR+/HER2- breast cancer, it carries significant toxicity, and many patients may not derive clinical benefit. Emerging evidence suggests that circulating tumor DNA (ctDNA)-a minimally invasive biomarker reflecting residual disease-may guide personalized treatment de-escalation.

Preclinical and clinical studies demonstrate that ctDNA dynamics correlate with tumor burden and prognosis. In HR+ breast cancer, ctDNA clearance after neoadjuvant therapy is associated with improved survival, while persistent ctDNA post-treatment predicts recurrence. CDK4/6 inhibitors, such as Dalpiciclib, have revolutionized advanced HR+/HER2- breast cancer management by enhancing endocrine therapy efficacy. However, their role in early-stage disease, particularly in a ctDNA-guided de-escalation strategy, remains underexplored. This study addresses this gap by evaluating whether ctDNA-driven decision-making can safely reduce chemotherapy use while maintaining clinical outcomes.

  • 2. Study Objectives

    1. Primary Objectives

      Group B (Experimental Arm):

      Assess ctDNA clearance rate (defined as conversion from detectable to undetectable ctDNA) after 4 cycles of neoadjuvant Dalpiciclib + aromatase inhibitor (AI).

      Evaluate 3-year event-free survival (EFS), where events include local/distant recurrence, secondary malignancies, or death.

    2. Secondary Objectives Compare safety profiles of Dalpiciclib + AI versus chemotherapy.

      Evaluate tumor response metrics:

      Pathological complete response (pCR) and residual cancer burden (RCB 0-1). Complete cell cycle arrest (CCCA; Ki67 ≤2.7%). Assess objective response rate (ORR) by RECIST 1.1.

    3. Exploratory Objectives Correlate ctDNA clearance with long-term outcomes (e.g., EFS, overall survival).

      Identify molecular signatures predictive of response to Dalpiciclib + AI.

  • 3. Study Design

    1. Overview

      This is a prospective, multicenter, randomized, open-label Phase II trial. Patients are stratified by clinical stage (I/II vs. III) and menopausal status, then randomized 1:4 to:

      Group A (Control): 4 cycles of taxane-based neoadjuvant chemotherapy (N=79). Group B (Experimental): 4 cycles of neoadjuvant Dalpiciclib (125 mg/day, 21 days on/7 days off) + AI (N=314).

    2. Post-Surgery Treatment Group A: Physicians may recommend adjuvant chemotherapy ± CDK4/6 inhibitors.

Group B:

ctDNA-negative post-neoadjuvant: Continue Dalpiciclib + AI for 2 years. ctDNA-positive post-neoadjuvant: Optional adjuvant chemotherapy followed by Dalpiciclib + AI.

  • 4. Study Population

    (1)key inclusion Criteria

    ①Women aged 18-75 with histologically confirmed HR+ (ER/PR ≥10%), HER2- early breast cancer.

    ②High-risk features: T1c-T2N0M0 with grade 3 histology or grade 2 + Ki67 ≥20%. T3N0M0. Any T with N+ and M0.

    • ECOG performance status 0-1. ④Adequate organ function (hematologic, hepatic, renal, cardiac). (2)key exclusion Criteria

      ①Metastatic disease, bilateral breast cancer, or prior breast malignancy.

      ②Active infections, cardiovascular comorbidities, or concurrent malignancies.

    • Pregnancy/lactation or refusal to use contraception.
  • 5. Interventions

    1. Neoadjuvant Phase

      Group A:

      Taxane regimens (e.g., paclitaxel 80 mg/m² weekly, docetaxel 75-100 mg/m² every 3 weeks).

      Group B:

      Dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) + AI (letrozole/anastrozole/exemestane).

    2. Adjuvant Phase Group B ctDNA-negative: Dalpiciclib + AI for 2 years. Premenopausal patients receive ovarian suppression (LHRH agonists).
  • 6. Assessments and Follow-Up

    1. ctDNA Analysis Baseline and Pre-Surgery: Tumor-informed personalized ctDNA panels (16 clonal variants via whole-exome sequencing).
    2. Efficacy and Safety ①Tumor imaging (MRI/CT) every 2 cycles during neoadjuvant therapy. ②Pathological evaluation of surgical specimens (RCB classification).

      ③Safety monitoring: Adverse events (NCI CTCAE v5.0), ECG, lab tests (hematology, chemistry).

    3. Follow-Up Schedule Treatment Phase: Clinic visits every 4 weeks (neoadjuvant) or 12 weeks (adjuvant).

Survival Follow-Up: Every 3 months post-treatment for recurrence and survival.

  • 7. Statistical Considerations

    1. Sample Size Primary Endpoint 1 (ctDNA clearance): 215 patients (Group B) provide 80% power to detect a 10% improvement over historical controls (40% vs. 50%, α=0.025).

      Primary Endpoint 2 (3-year EFS): 314 patients (Group B) provide 80% power to detect a 5% absolute improvement (85% vs. 90%, α=0.05).

      Total enrollment: 393 (1:4 randomization).

    2. Analysis Populations Intent-to-Treat (ITT): All randomized patients with ≥1 post-baseline assessment.

      Safety Set (SS): Patients receiving ≥1 dose of study treatment.

    3. Statistical Methods ctDNA clearance rate: Clopper-Pearson exact 95% CI. EFS: Kaplan-Meier estimates with log-rank tests. Subgroup analyses by stratification factors.
  • 8. Ethical and Regulatory Considerations

    ①Approved by institutional review boards at all participating centers.

    ②Written informed consent required before screening.

    ③SAEs reported to regulators within 24 hours.

    ④Independent Data Monitoring Committee (IDMC) oversees safety and futility.

  • 9. Innovation and Impact

This trial pioneers a ctDNA-guided de-escalation strategy in early HR+ breast cancer, addressing two critical unmet needs:

Reducing chemotherapy overuse in patients likely cured by targeted therapy. Validating ctDNA as a dynamic biomarker for real-time treatment adaptation. If successful, the study could establish a new paradigm for personalized adjuvant therapy, minimizing toxicity while maintaining survival outcomes.

03

Conditions studied

  • Hormone Receptor-Positive Breast Cancer
  • High-risk Breast Cancer
  • Early-Stage Breast Cancer
  • HER2-negative Breast Cancer
  • ctDNA Monitoring
  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Browse trials for

Keywords

  • HR-positive HER2-negative breast cancer
  • Early-stage breast cancer
  • Dalpiciclib
  • CDK4/6 inhibitor
  • ctDNA-guided therapy
  • Adjuvant chemotherapy de-escalation
  • Circulating tumor DNA (ctDNA)
  • Event-free survival (EFS)
  • Chemotherapy sparing
  • Personalized therapy
  • Biomarker-guided therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female breast cancer patients aged ≥18 years and ≤75 years, either or premenopausal/perimenopausal;
  • confirmed hormone receptor-positive (HR+), -negative invasive breast cancer:

    1. ER-positive and/or PR-positive defined as: ≥10% of tumor cells showing positive staining;
    2. HER2-negative defined as: standard immunohistochemistry (IHC) result of 0/1+; or IHC 2+ with negative in situ hybridization (ISH) (confirmed by the central pathology laboratory);
  • At least one evaluable lesion per 1.1, with clinical staging meeting:

    1. T1c-2N0M0 with high-risk factors (Grade 3, or Grade 2 with Ki67 ≥20%);
    2. T3N0M0;
    3. Any TN+M0;
  • (ECOG) performance status score of 0-1;
  • Willing to participate in the study and voluntarily sign ;
  • Agree to undergo ctDNA testing during treatment;
  • Adequate organ and bone marrow function defined as:

    1. (ANC) ≥1,500/mm³ (1.5 × 10⁹/L) (without granulocyte colony-stimulating factor [G-CSF] treatment within 14 days);
    2. count (PLT) ≥100,000/mm³ (100 × 10⁹/L) (without corrective therapy within 7 days);
    3. (Hb) ≥9 g/dL (90 g/L) (without corrective therapy within 7 days);
    4. Serum creatinine ≤1.5× (ULN) or ≥60 mL/min (without corrective therapy within 7 days);
    5. Total (TBIL) ≤1.5×ULN (without corrective therapy within 7 days);
    6. (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤1.5×ULN (without corrective therapy within 7 days);
    7. Cardiac function: (LVEF) ≥55%; corrected by Fridericia's formula (QTcF) \<470 msec on 12-lead ;
  • Women of must have a negative serum pregnancy test within 7 days prior to randomization and agree to use non-hormonal from informed consent signing until 2 months after the last treatment.

Exclusion criteria

Exclusion Criteria:

  • -positive breast cancer confirmed by current pathological diagnosis;
  • Inflammatory breast cancer;
  • Stage IV () breast cancer;
  • Bilateral breast cancer;
  • Prior history of breast cancer (including ductal carcinoma in situ or invasive breast cancer);
  • Any prior antitumor therapy for the current breast cancer, including systemic therapies (endocrine, chemotherapy, immunotherapy, biological therapy) or local therapies (radiotherapy, vascular embolization, axillary lymph node );
  • Diagnosis of any within 5 years prior to randomization, except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin;
  • History of severe pulmonary diseases (e.g., interstitial pneumonia);
  • infection, acquired immunodeficiency syndrome (AIDS), active (HBV DNA ≥500 IU/mL), (HCV antibody-positive with HCV RNA above the lower limit of detection), or co-infection with HBV and HCV;
  • Within 6 months prior to randomization: myocardial infarction, severe/unstable angina, Class ≥II heart failure, ≥Grade 2 persistent arrhythmia (per v5.0), atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (including ), or symptomatic pulmonary embolism;
  • Severe active infection within 4 weeks prior to randomization (requiring intravenous antibiotics, antifungals, or antivirals) or unexplained fever >38.5°C during screening/before first dose;
  • Known allergy to any component of the study drugs;
  • Current participation in another interventional drug clinical study;
  • Pregnancy or lactation;
  • Refusal to comply with follow-up;
  • Other severe physical/mental illnesses or laboratory abnormalities that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
393 participants (estimated)

Study arms

  • Active comparator
    Taxane Neoadjuvant Chemo ± Adjuvant Therapy

    Arm Description: This group receives neoadjuvant taxane-based chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly for 4 cycles) before surgery. Post-surgery adjuvant chemotherapy (whether or not and how to adopt depend on the physician's choice) may be administered ± CDK4/6 inhibitors. The intervention aims to compare standard chemotherapy efficacy as a control. Intervention phases: * Neoadjuvant: Chemotherapy only * Adjuvant: Optional chemotherapy based on physician discretion ± (CDK4/6 inhibitors+endocrine therapy) Key endpoints: Pathological response 0/1 (RCB 0/1), safety profiles.

    Drug: Taxane-Based Neoadjuvant Chemotherapy

  • Experimental
    Dalpiciclib + AI with ctDNA-Driven Adjuvant

    Arm Description: Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg/day, 21 days on/7-off) combined with aromatase inhibitors (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: 1. ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years. 2. ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% : Randomized 1:1 to: * Arm B1: Dalpiciclib + ET for 2 years. * Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years. 3. Persistently ctDNA-positive or ctDNA-negative → positive: Adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women receive ovarian suppression with LHRH agonists.

    Drug: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy

Interventions

  • DrugDalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy

    Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) combined with an aromatase inhibitor (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: (1)ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years; (2)ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% :Randomized 1:1 to: * Arm B1: Dalpiciclib + ET for 2 years. * Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years;(3)Persistently ctDNA-positive or ctDNA-negative → positive: Mandatory adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women undergo ovarian suppression with LHRH agonists.

    Also known as: Dalpiciclib/AI combination therapy, SHR6390 + aromatase inhibitor

  • DrugTaxane-Based Neoadjuvant Chemotherapy

    Patients receive 4 cycles of taxane-based neoadjuvant chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly) before surgery. Post-surgery adjuvant chemotherapy (physician's choice) may be administered. This arm serves as the control group for comparing standard chemotherapy efficacy.

    Also known as: Paclitaxel/cyclophosphamide neoadjuvant therapy, Docetaxel-based chemotherapy regimen

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. ctDNA Clearance Rate after Neoadjuvant Therapy

    Proportion of patients in Group B achieving conversion from detectable to undetectable ctDNA in plasma after 4 cycles of neoadjuvant Dalpiciclib + aromatase inhibitor. ctDNA analysis uses tumor-informed personalized panels (tracking 16 clonal variants via whole-exome sequencing), with clearance defined as ≥2 consecutive negative results at 1% variant allele frequency threshold.

    Time frame: From baseline to 4 weeks post-neoadjuvant therapy (pre-surgery)

  2. 3-Year Event-Free Survival (EFS)

    Time from randomization to first occurrence of locoregional/distant recurrence, contralateral breast cancer, secondary malignancy, or death from any cause. Assessed via imaging (CT/MRI), pathology, and clinical exams every 3 months for 3 years. Events are adjudicated by blinded independent review committee.

    Time frame: From randomization to 36 months post-surgery

Secondary outcomes

  1. Incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs)

    Proportion of patients experiencing grade ≥3 adverse events (per NCI CTCAE v5.0) related to Dalpiciclib + AI or chemotherapy, including hematologic (neutropenia, anemia), hepatic (ALT/AST elevation), and cardiac (LVEF decline ≥10%) toxicities. Events are monitored every cycle during neoadjuvant therapy and quarterly during adjuvant phase.

    Time frame: From first dose to 30 days after last treatment (up to 26 months)

  2. Residual Cancer Burden (RCB) 0-1 Rate

    Proportion of patients achieving RCB 0 (pathological complete response) or RCB-1 (minimal residual disease) in surgical specimens. RCB is calculated using standardized criteria (tumor bed area, cellularity, nodal involvement) by blinded central pathology review.

    Time frame: At surgery (approximately 16 weeks after randomization)

  3. Complete Cell Cycle Arrest (CCCA) Rate (Ki67 ≤2.7%)

    Percentage of patients with Ki67 ≤2.7% in post-neoadjuvant tumor biopsies, assessed via immunohistochemistry (IHC) with 3,3'-diaminobenzidine staining. Central laboratory quantification uses Aperio image analysis system (Leica Biosystems).

    Time frame: Post-neoadjuvant therapy (pre-surgery, week 16)

  4. Objective Response Rate (ORR) by RECIST 1.1

    Proportion of patients with complete/partial response per RECIST 1.1 criteria during neoadjuvant phase, measured by MRI/CT. Target lesion size reduction ≥30% (partial) or disappearance (complete) required, confirmed by two consecutive assessments ≥4 weeks apart.

    Time frame: Baseline to pre-surgery (week 16)

  5. Correlation Between ctDNA Clearance and 3-Year EFS

    Exploratory analysis of the association between ctDNA clearance status (post-neoadjuvant) and 3-year EFS using Cox proportional hazards models. ctDNA dynamics (baseline, post-treatment) are analyzed as time-dependent covariates.

    Time frame: From baseline to 36 months post-surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly due to: Patient Privacy Protection: Genomic data (e.g., ctDNA variants) and medical records contain identifiable health information protected under China's Personal Information Protection Law (PIPL). Institutional Policy: Peking University People's Hospital requires data use agreements (DUA) for external access to clinical trial data. Ethical Restrictions: The approved protocol prohibits open data sharing to prevent potential misuse of sensitive biomarker results. De-identified data may be available upon reasonable request to the Principal Investigator after: Completion of primary endpoint analysis (2030 Q1) of a DUA with confidentiality clauses Approval by the hospital's data oversight committee Interested researchers may contact [PI Email] for access criteria.'

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2029, 52 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 52 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970912
Responsible party
Shu Wang (director of breast center, Peking University People's Hospital) — Principal investigator
First posted
May 14, 2025
Start date
Aug 1, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

yuan peng, doctor
Contact
13671287670@163.com
86+13671287670
shu wang, doctor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Exemestane

Start the discussion